Clinical trials: Human Immunodeficiency Virus Type 1
HIV/AIDS
Safety, Tolerability and Immunogenicity of MVA.HTI and ChAdOx1.HTI With Vesatolimod in HIV-1 Positive Patients
AELIX-003 study aims to investigate the safety, tolerability, immunogenicity and efficacy of a regimen containing AELIX Therapeutics' HTI T-cell vaccines and Gilead´s Toll-Like Receptor 7 (TLR7) agonist vesatolimod in…
- Trial name
- AELIX-003 (NCT04364035)
- Testing
- ChAdOx1.HTI, MVA.HTI, GS-9620
- Where
- 9 sites in Spain
- Volunteers
- 50 people
- Sponsor
- Aelix Therapeutics
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers
This research study is being conducted to evaluate an experimental drug called huCART19-IL18-CD428z cells in patients living with HIV who have been diagnosed with Non-Hodgkin Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL)…
- Conditions
- Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Richter's Transformation
- Trial name
- NCT07891468
- Testing
- huCART19-IL18-CD428z cells
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Pennsylvania
HIV Infections
A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects
To evaluate the safety and immunogenicity of a combination of microparticulate monovalent HIV-1 MN synthetic branched peptide candidate vaccine for oral administration and monovalent HIV-1 MN synthetic branched peptide vaccine in…
- Trial name
- NCT00002428
- Testing
- HIV-1 Peptide Vaccine, Microparticulate Monovalent, rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- United Biomedical
Healthy Subjects
Observational Study of the Preventive Trial With HIV-1 Tat Protein
The results of the Phase I Safety and Immunogenicity Trial of Recombinant HIV-1 Tat (ISS P-001 and ISS T-001) indicate that the vaccine based on the recombinant Tat protein is safe, well tolerated and immunogenic.
- Trial name
- ISS OBS P-001 (NCT01024764)
- Where
- 3 sites in Italy
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Istituto Superiore di Sanità
HIV-1 Infection
Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
The primary objective of this study is to evaluate the efficacy of switching from a regimen of 2 nucleos(t)Ide reverse transcriptase inhibitors (NRTIs) and a third agent to a fixed dose combination (FDC) of…
- Trial name
- BRAAVE 2020 (NCT03631732)
- Testing
- B/F/TAF, NRTIs, Third Agent
- Where
- 82 sites in United States
- Volunteers
- 496 people
- Sponsor
- Gilead Sciences
HIV Infections
Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults
This study will test the safety of and immune system response to a new HIV vaccine. The vaccine in this study is made from HIV DNA produced in a laboratory.
- Trial name
- NCT00069030
- Testing
- VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade-Env) with adjuvant VRC-ADJDNA004-IL2-VP
- Where
- 7 sites in United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients
A 2-year multicenter, phase II/III, randomized active-controlled trial to evaluate the efficacy and tolerance of two maintenance strategies in HIV-1 infected patients with HIV RNA below 50 copies/mL : a monotherapy with…
- Trial name
- ANRS 140 DREAM (NCT00946595)
- Testing
- efavirenz/emtricitabin/tenofovir, lopinavir/ritonavir
- Where
- France
- Volunteers
- 420 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV-1-infection
10E8.4/iMab Bispecific Antibody in HIV-uninfected and HIV-infected Adults
Many HIV-infected individuals mount a broad neutralizing serologic response 2-3 years after infection. Broadly neutralizing antibodies might play an important role in protection from acquisition of HIV infection because they can…
- Trial name
- NCT03875209
- Testing
- 10E8.4/iMab
- Where
- 2 sites in United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- David Ho
HIV Infections
Phase 2b, Open-label, Multicenter, Rollover Study to Assess Antiviral Activity and Safety of Long-acting (LA) Cabotegravir (CAB) Plus LA Rilpivirine (RPV), Administered Every 2 Months (Q2M), in Human Immunodeficiency Virus (HIV)-Positive Participants From the LATTE Study
This study (POLAR), is designed to assess the antiviral activity and safety of CAB LA plus RPV LA, administered Q2M, in approximately 100 adult HIV-1 infected, antiretroviral therapy (ART) experienced participants.
- Trial name
- NCT03639311
- Testing
- CAB LA, RPV LA, RPV
- Where
- 30 sites in United States, Canada
- Volunteers
- 97 people
- Sponsor
- ViiV Healthcare
HIV-1 Infection
Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients
The goal of antiretroviral therapy should be maintaining undetectable plasma viral load, only present condition to prevent the progression of the disease, improve immune restoration and prevent the emergence of viral resistance…
- Trial name
- ATALOW (NCT02473328)
- Testing
- Atazanavir 200 mg/r
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
HIV Infections
Phase I Study of Safety and Persistence of UC-781 Vaginal Microbicide
Vaginal microbicides are compounds that may protect women from HIV and other sexually transmitted infections (STIs). This study will determine the safety of the microbicide UC-781 by comparing the effects of keeping the…
- Trial name
- NCT00441909
- Testing
- UC-781
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acquired Immunodeficiency Syndrome, HIV Infection
White Blood Cell Infusions to Treat HIV Infection
This study will evaluate the safety and immune system effects of infusing HIV-infected patients with multiple doses of lymphocytes (white blood cells) from their non-infected identical twin.
- Trial name
- NCT00001647
- Testing
- White blood cell infusion
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection
Open-Label Multi-Centre Randomised Switch Study to Evaluate Virological Efficacy Over 96Weeks Of 2-Drug Therapy With Dolutegravir(DTG)/Rilpivirine(RPV) Fixed Dose Combination(FDC) in Antiretroviral Treatment-Experienced HIV-1 Infected Subjects Virologically Suppressed With NNRTI Mutation K103N
HIV-1 infected subjects that experience virological failure while on non nucleoside reverse-transcriptase inhibitors (NNRTIs), including those with the K103N mutation, are usually switched to a boosted Protease Inhibitor…
- Trial name
- WISARD (NCT05349838)
- Testing
- Dolutegravir & Rilpivirine 2 drug fixed dose combined therapy
- Where
- 29 sites in Belgium, France and 4 more
- Volunteers
- 140 people
- Sponsor
- NEAT ID Foundation
HIV Infections
Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals
The purpose of the study is to determine the safety of mucosal immune responses to a DNA HIV vaccine followed by an adenoviral vector HIV vaccine in HIV uninfected adults.
- Trial name
- NCT00955006
- Testing
- VRC-HIVDNA-016-00-VP, VRCHIVADV014-00-VP
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection
A Test and Treat Strategy in New HIV Diagnosis.
This is an open-label, single arm, single-centre prospective study to evaluate the feasibility, efficacy and safety of a once daily fixed dose combination regimen, Biktarvy, as a rapid treatment strategy in newly HIV diagnosed…
- Trial name
- Test&Treat (NCT04416906)
- Testing
- Biktarvy
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Judit Pich Martínez
HIV Infections
Safety of and Immune Response to a DNA HIV Vaccine (VRC-HIVDNA009-00-VP) in HIV Infected Individuals With Acute HIV Infection
The purpose of this study is to evaluate whether the HIV vaccine VRC-HIVDNA009-00-VP will be safe in individuals who started antiretroviral therapy during acute HIV-1 infection.
- Trial name
- NCT00125099
- Testing
- VRC-HIVDNA009-00-VP
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV -1 Infection, Methamphetamine Use
Short-term Effects of Methamphetamine on Residual Latent HIV Disease Study
The most commonly used illicit stimulant in people with HIV (PWH) is methamphetamine (MA). Prior studies demonstrate strong evidence that MA promotes increased HIV transcription as well as immune dysregulation.
- Trial name
- EMRLHD (NCT07584369)
- Testing
- Oral Methamphetamine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
HIV Infections
Switch to TAF+FTC+BIC in HIV-1-infected Patients Over 65 Years Old at Risk of Polymedication
Patients infected and living with HIV are getting older and have more and more non-HIV co-morbidities. These expose them to polypharmacy that increases the risk of pharmacological interaction.
- Trial name
- BICOLDER (NCT04222283)
- Testing
- BIKTARVY 50Mg-200Mg-25Mg Tablet
- Where
- 8 sites in France
- Volunteers
- 27 people
- Sponsor
- Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
HIV Infections
Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults
NOTE: This study has stopped enrolling new participants, and all study vaccinations for currently enrolled participants have been stopped.
- Trial name
- NCT01783977
- Testing
- DNA-HIV-PT123 vaccine, NYVAC-HIV-PT1 vaccine, NYVAC-HIV-PT4 vaccine
- Where
- 8 sites in United States, Switzerland
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection
Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission
This is a phase I, randomized, open-label trial to investigate the safety of VRC07-523LS, PGDM1400LS and N-803 in combination with Ad26.Mos4.HIV, MVA-Bavarian Nordic (BN)-HIV and A244d11gp120/ALFQ vaccination, and the impact on…
- Trial name
- RV582 (NCT05769569)
- Testing
- VRC07-523LS, PGDM1400LS, N-803
- Where
- 2 sites in Thailand
- Volunteers
- healthy volunteers welcome
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.